Ascendis raises $225M in bumped-up follow-on

Endocrinology company Ascendis Pharma A/S (NASDAQ:ASND) raised $225 million on Feb. 22 through the sale of 3.9 million ADSs at $57 in a bumped-up follow-on underwritten by J.P. Morgan, BofA Merrill Lynch, Credit Suisse, Wells Fargo, Stifel and Wedbush PacGrow. The price was a 3% discount to Ascendis' closing price of $59 on Feb. 20, when the company proposed after market hours to raise $150 million...